indeed my hunch is also that ple will be downplayed and used for support of scenesse-safety profile. PLE was similar to epp an indication identified by OLD management (including Agersborg) not mr Wolgen.
Also in the past 10 years since the re-focus on ple the FDA and EMA have to say it mildly changed focus. No way this kind of indication would currently result in a MA.
Even for SU they got wacked by EMA and FDA because they say current treatment with cortisones is available and cheap so no need for Scenesse. You see how patient interests are squeezed here? I start wishing that if EMA dont approve scenesse or label expansion Wolgen would take all leftover money and move his 20 staff to China and sell via internet to all the patients in EU and US. Not bad for an alternative plan no?
CUV Price at posting:
$1.70 Sentiment: ST Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)